Exenatide Once Weekly Plus Metformin for the Treatment of Type 2 Diabetes Mellitus: A Network Meta Analysis of Randomised Controlled Trials.
Table 1. Relative effect sizes for change of HbA1c, risk of nausea and treatment discontinuation due to AEs, all GLP 1 RA treatments compared to placebo. In addition to GLP 1 RAs, two sulfonylureas (glibenclamide, glimepiride) two thiazolidinediones (rosiglitazone, pioglitazone) the dipeptidyl peptidase 4 inhibitor sitagliptin and insulin were included to ensure a connected network of comparative trials when direct evidence was not available. Results are presented only for GLP1RAs.
Value in health the journal of the International Society for Pharmacoeconomics and Outcomes Research